New York attorney general probes insurers over hepatitis C drug coverage

New York attorney general probes insurers over hepatitis C drug coverage
By: Joe Barber

New York Attorney General Eric Schneiderman has subpoenaed 16 insurers to determine whether they are inappropriately denying patients access to new hepatitis C drugs. According to sources, the attorney general's office has requested information on patients who were denied coverage for the medicines. People familiar with the matter noted that the initial two subpoenas specifically requested documentation regarding coverage of Gilead Sciences' Harvoni (ledipasvir/sofosbuvir), while the remaining subpoenas did not mention a specific drug.

Continue reading....

Related News
Massachusetts Attorney General considering legal action against Gilead over drug prices
US lawmakers allege Gilead used "revenue-driven" pricing model for hepatitis C drugs
Gilead's hepatitis C drug Harvoni selected by health insurer Anthem
Wider Reach Is Sought for Costly New Hepatitis C Treatments
Actavis sued by New York Attorney General over planned Namenda switch

Reference Articles
New York Said to Investigate Insurers Over Hepatitis C Drugs - (Bloomberg)
New York’s attorney general is going after a new target in the debate over costly drugs - (Daily News)
New York's attorney general is investigating whether insurance companies may be unfairly limiting coverage for a costly drug - (Business Insider)
Insurers Probed on Hepatitis C Drug Coverage - (The Wall Street Journal)